Lipid-Embedded Microcapsules with Polysaccharide Coating for Colon Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for colonic disorders face challenges in effectively targeting and releasing active agents, such as short chain fatty acids, specifically butyrate, to the colon, with limited efficacy due to gastric digestion and variable enzyme activity, necessitating improved delivery mechanisms for lipophilic and water-insoluble agents.
Innovation Solution
Microcapsules with a polymeric coating crosslinked with a polysaccharide matrix embedding lipids and active agents or their prodrugs, where the lipid has a melting point of at least 30 °C, are developed, allowing for stable delivery to the colon by resisting digestion in the upper gastrointestinal tract and releasing the active agent in the colon.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a lipid matrix is used to embed lipophilic active agents, then the stability and targeted delivery to the colon is improved, but the complexity of the delivery system increases
Solution Approach 1:
The patent employs a composite microcapsule structure consisting of a lipid matrix core embedding the active agent, surrounded by a polysaccharide coating layer. This composite design combines the lipophilic properties of the lipid matrix for effective active agent incorporation with the protective and targeted delivery capabilities of the polysaccharide coating, resolving the contradiction between improved targeted delivery and system complexity by integrating multiple functional materials into a unified microcapsule system.
Solution Approach 2:
The microcapsule structure implements a nested configuration where the active agent is embedded within the lipid matrix, which in turn is encapsulated by the polysaccharide coating. This nested arrangement allows the lipid matrix to provide a stable environment for lipophilic agents while the outer polysaccharide layer provides protection and targeted delivery, achieving reliable colon-specific delivery without requiring separate complex systems for each function.
2Stability of the object's composition
If the polymeric coating is crosslinked with the polysaccharide matrix, then the stability of the microcapsules against gastric digestion is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent utilizes parameter changes in the form of pH-responsive behavior during the crosslinking process. The polysaccharide coating (such as chitosan) undergoes crosslinking with the lipid matrix under specific pH conditions, forming a stable gel structure that resists gastric digestion. By controlling the pH parameter during manufacturing, the crosslinking degree and microcapsule stability can be optimized, balancing the improved digestive resistance with manageable manufacturing precision requirements.
3Duration of action of moving object
If lipids with melting point of at least 30 °C are used in the matrix, then the controlled release of active agents in the colon is improved, but the difficulty of detecting and measuring the release mechanism increases
Solution Approach 1:
The patent exploits phase transitions of the lipid matrix as the primary release mechanism. Lipids with melting points of at least 30°C undergo solid-to-liquid phase transition in the colonic environment, enabling controlled release of the embedded active agent. This phase transition mechanism provides sustained release over an extended duration as the lipid gradually melts and releases the active agent, while the transition itself serves as a detectable physical change that can be monitored through differential scanning calorimetry or other thermal analysis methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microcapsules provide stable and targeted delivery of active agents to the colon, enhancing the treatment of colonic disorders like diarrhea and colon cancer by maintaining the integrity of the active agents until they reach the colon, thereby improving therapeutic efficacy and reducing adverse side reactions.
Implementation Method 1
a lipid and an active agent or a prodrug or salt thereof are embedded, the lipid having a melting point of at least 30 °C... resisting digestion in the upper gastrointestinal tract and releasing the active agent in the colon
Implementation Method 2
Microcapsules with a polymeric coating crosslinked with a polysaccharide matrix... the polymeric coating being at least partly crosslinked with a polymeric matrix comprising a polysaccharide
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to microcapsules and to methods for preparing the same, the microcapsules comprising a polymeric coating, the polymeric coating being at least partly crosslinked with a polymeric matrix comprising a polysaccharide, wherein in the matrix a lipid and an active agent or a prodrug or salt thereof are embedded, the lipid preferably having a melting point of at least 30 °C. Furthermore, the present invention relates to microcapsules for use as a medicament, dietary supplement or food additive, the microcapsules comprising a polymeric coating, the polymeric coating being at least partly crosslinked with a polymeric matrix comprising a polysaccharide, wherein in the matrix a lipid and an active agent or a prodrug or salt thereof are embedded, the lipid preferably having a melting point of at least 30 °C. Further, the present invention relates to a method for treating diarrhoea or preventing colon cancer comprising administering such microcapsules.